Literature DB >> 8990000

A phase I study of vaccination with autologous, irradiated melanoma cells engineered to secrete human granulocyte-macrophage colony stimulating factor.

G Dranoff1, R Soiffer, T Lynch, M Mihm, K Jung, K Kolesar, L Liebster, P Lam, R Duda, S Mentzer, S Singer, K Tanabe, R Johnson, A Sober, A Bhan, S Clift, L Cohen, G Parry, J Rokovich, L Richards, J Drayer, A Berns, R C Mulligan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 8990000     DOI： 10.1089/hum.1997.8.1-111

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN： 1043-0342            Impact factor:   5.695


× No keyword cloud information.
  9 in total

1.  Recombinant yellow fever viruses are effective therapeutic vaccines for treatment of murine experimental solid tumors and pulmonary metastases.

Authors:  A McAllister; A E Arbetman; S Mandl; C Peña-Rossi; R Andino
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

Review 2.  Prospects for vaccination in prostate cancer.

Authors:  M J Perry; D Hroulda; A G Dalgleish
Journal:  Drugs Aging       Date:  2000-05       Impact factor: 3.923

Review 3.  Potential use of T cell receptor genes to modify hematopoietic stem cells for the gene therapy of cancer.

Authors:  T M Clay; M C Custer; P J Spiess; M I Nishimura
Journal:  Pathol Oncol Res       Date:  1999       Impact factor: 3.201

4.  Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma.

Authors:  R Soiffer; T Lynch; M Mihm; K Jung; C Rhuda; J C Schmollinger; F S Hodi; L Liebster; P Lam; S Mentzer; S Singer; K K Tanabe; A B Cosimi; R Duda; A Sober; A Bhan; J Daley; D Neuberg; G Parry; J Rokovich; L Richards; J Drayer; A Berns; S Clift; L K Cohen; R C Mulligan; G Dranoff
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-27       Impact factor: 11.205

5.  CML28 is a broadly immunogenic antigen, which is overexpressed in tumor cells.

Authors:  Xiao-Feng Yang; Catherine J Wu; Linyun Chen; Edwin P Alyea; Christine Canning; Philip Kantoff; Robert J Soiffer; Glenn Dranoff; Jerome Ritz
Journal:  Cancer Res       Date:  2002-10-01       Impact factor: 12.701

6.  Preferential targeting of disseminated liver tumors using a recombinant adeno-associated viral vector.

Authors:  Marco Della Peruta; Adam Badar; Cecilia Rosales; Shilpa Chokshi; Azadeh Kia; Devhrut Nathwani; Eva Galante; Ran Yan; Erik Arstad; Andrew M Davidoff; Roger Williams; Mark F Lythgoe; Amit C Nathwani
Journal:  Hum Gene Ther       Date:  2015-02       Impact factor: 5.695

7.  Immunohistochemical localization of CD1a-positive putative dendritic cells in human breast tumours.

Authors:  E E Hillenbrand; A M Neville; B J Coventry
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

Review 8.  Therapeutic cancer vaccines: past, present, and future.

Authors:  Chunqing Guo; Masoud H Manjili; John R Subjeck; Devanand Sarkar; Paul B Fisher; Xiang-Yang Wang
Journal:  Adv Cancer Res       Date:  2013       Impact factor: 6.242

9.  Neoantigen-based EpiGVAX vaccine initiates antitumor immunity in colorectal cancer.

Authors:  Victoria M Kim; Xingyi Pan; Kevin C Soares; Nilofer S Azad; Nita Ahuja; Christopher J Gamper; Alex B Blair; Stephen Muth; Ding Ding; Brian H Ladle; Lei Zheng
Journal:  JCI Insight       Date:  2020-05-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.